Abstract 1788
Background
PET/CT is an essential component in the initial assessment of locally advanced NSCLC. However, the role of PET/CT in the assessment of response to therapies is not well established.
Methods
We reviewed all stage III NSCLC patients assessed at our centre between January 2009 and March 2018, selecting those with PET/CT evaluation at diagnosis and after treatment (chemotherapy and/or radiotherapy). We evaluated the prognostic differences between mayor PET/CT response (reduction of ≥ 50% of initial SUVmax), minor PET response (reduction of < 50%) and absence of response, by Cox regression. We assessed the predictive value of PET/CT for pathological response in both tumour and mediastinal nodes in patients who had undergone surgery after an induction treatment.
Results
We reviewed 249 patients. In 92,3% an initial PET/CT evaluation was carried out. 117 patients (46.9%) had a PET/CT re-evaluation after an initial chemotherapy and/or radiotherapy treatment. We observed a higher risk of disease progression in patients with a minor PET/CT response (HR 1.97; IC95% 1.2-3.2) and without a response (HR 2.3; IC95% 1.4-4.6, p < 0.01). Progression free survival (PFS) at 12 months was 73%, 47% and 32% among patients with a mayor response, a minor response and no response, respectively. Differences in overall survival (OS) did not reach statistical significance (p = 0,06), but a higher risk for death was seen with a minor response (HR 1.7; IC95%, 1-2,9) and no response (HR 2.1; IC95%, 1,2-3,9). 37 patients (14.9%) underwent surgery after an induction treatment. A greater reduction of SUVmax was observed when pathological response was achieved (mean SUVmax reduction of 94% with complete pathological response vs 27% in absence of response). 22 patients with N2 disease pre-induction therapy underwent surgery. SUVmax reduction was higher in patients with a response (60% vs 35%). However, post-induction mediastinal SUVmax > 2.5 presented a sensitivity of only 42.9% and a specificity of 87.5%.
Conclusions
PET/CT response after induction therapy was a good prognosticator for PFS and OS in stage III NSCLC patients. However, response evaluation by PET/CT should be interpreted with caution due to its lack of precision.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Calvo de Juan: Honoraria (self): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Boerhinger; Honoraria (self): Roche. M. Provencio: Honoraria (self), Research grant / Funding (institution): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boerhinger. All other authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract